GlassScriptPhysician profile
Megan D Turner
NPI 1477164499
$4,856.65
in general payments reported to CMS, 2019-2025
22 companies · $1,373 in 2025
The $1,373 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $87.75 · 2023: $1,031 · 2024: $2,265 · 2025: $1,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,394 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,393.60 |
| Education | $274.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,017.38 | 2023-2025 | |
| Janssen Biotech, INC. | $696.96 | 2023-2025 | Tremfya, Simponi, Stelara |
| Incyte Corporation | $611.67 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $523.30 | 2023-2025 | |
| Genzyme Corporation | $415.67 | 2023-2025 | |
| Amgen INC. | $323.76 | 2023-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $305.25 | 2023-2025 | Sotyktu |
| Ucb, INC. | $195.92 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $144.21 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $116.60 | 2023-2024 | Dupixent, Libtayo |
| Organogenesis INC. | $100.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Bioventus LLC | $66.82 | 2022 | |
| Mallinckrodt Hospital Products INC. | $54.88 | 2025 | Acthar |
| Leo Pharma INC. | $53.38 | 2025 | Spevigo, Anzupgo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $29.35 | 2025 | Gomekli |
| Lnhc, INC | $24.68 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.41 | 2024 | Spevigo |
| Krystal Biotech INC | $21.22 | 2025 | Vyjuvek |
| Smith+Nephew, INC. | $20.93 | 2022 | |
| Almirall LLC | $15.46 | 2023 | Klisyri |
| Mayne Pharma Commercial LLC | $14.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.